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Abstract
Resistance to enzyme replacement therapy (ERT) is a major therapeutic challenge in Fabry disease (FD). Recent reports attri-
bute to immune-mediated inflammation a main role in promoting disease progression and resistance to ERT. Aim of the study
is to report a Gb3-induced auto-reactive panmyocarditis causing inefficacy of ERT and severe electrical instability, which re-
quired cardiac transplantation. Examining the explanted heart from a 57-year-old man with FD cardiomyopathy (CM) on
3-year ERT presenting incoming ventricular fibrillation, we documented a severe virus-negative myocarditis extended to
cardiomyocytes, intramural coronary vessels, conduction tissue, and subepicardial ganglia. Serology was positive for anti-
Gb3, anti-heart, and anti-myosin antibodies. In vitro Gb3 stimulation of patient’s peripheral blood mononuclear cells (PBMC)
induced high amount production of inflammatory cytokine IL1-β, IL-6, IL-8, and TNF-α. PBMC were stained using the monoclo-
nal antibodies CD3-V500, CD4-V450, CD8-APCcy7, CD45RO-PerCPcy5.5 and CD27-FITC from BD Biosciences and CD56-PC7
from Bekman Coulter. The phenotypic analysis of PBMC showed a lower frequency of CD8 (9.2%) vs. 19.3% and NKT cells
(1.6% vs. 2.4%) in Fabry patient respect to healthy donor, suggesting a possible homing to peripheral tissues. A
Gb3-induced auto-reactive myocarditis is suggested as a possible cause of FDCM progression and ERT resistance.
Immune-mediated inflammation of systemic Fabry cells may coexist and be controlled by implemental immunosuppressive
therapy.
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Introduction
Fabry disease (FD) is an X-linked inborn error of
glycosphingolipid catabolism caused by deleterious mutations
in the GLA (a-galactosidase A) gene encoding the lysosomal
hydrolase GAL.1,2 The marked deficiency or absence of GAL
activity results in the systemic accumulation of
globotriaosylceramide (Gb3) and related glycosphingolipids
within the lysosomes, particularly in microvascular endothe-
lial cells, vascular smooth muscle cells, renal tubular cells,
podocytes, and cardiomyocytes.3–7
FD cardiomyopathy (FDCM) is a major determinant of pa-
tient survival, and its management represents a main
therapeutic challenge. Indeed, the impact of enzyme replace-
ment therapy (ERT) on FDCM is still controversial,8–12 and al-
though there is agreement that early ERT administration,
particularly in pre-hypertrophic FDCM, prevents progression
of the disease, the advanced form is believed to be irrevers-
ible. Mechanisms of resistance to ERT are still unclear, al-
though expansion of interstitial space and myocardial
fibrosis appear to be implicated.
To this regard, there is growing evidence that a constitu-
tional secretory pathway of Gb3 from affected cells limits cell
engulfment and death, allowing patient survival even in case
of absent enzyme activity. Furthermore, there is general
agreement on the ability of the extracellular
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glycosphingolipids to promote a pro-inflammatory response.
A recent report13 on a large population with FDCM receiving
a diagnostic endomyocardial biopsy documents an elevated
incidence (56%) of immune-mediated myocarditis reaching
the figure of 72% in the cohort with the most advanced phase
of the disease (maximal left ventricular wall
thickness > 20 mm). These data suggest that a
Gb3-induced auto-reactive inflammation of Fabry cells would
play a major role in the progression of FDCM as well as in its
resistance to ERT. The following study, analysing an explanted
heart with FDCM on a 3-year ERT, provides a strong evidence
that all affected components of the myocardium including
cardiomyocytes, coronary vessels, conduction tissue, and car-
diac ganglions can be involved by inflammation causing an in-
cessant electrical instability and the need for cardiac
transplantation.
Methods
A severely hypertrophied explanted heart weighting 785 g
was examined and processed for histology, electron micros-
copy, immunohistochemistry, and polymerase chain reaction
for viral genomes. In addition, serum samples collected at the
time of transplantation were tested for presence of anti-
heart, anti-myosin, and anti-Gb3 antibodies.
The explanted heart was transversely cut in sections of
1 cm thick, divided, mapped, and processed in paraffin
blocks of 1.5 × 2.5 cm. Paraffin sections of 5 micron were
stained with H&E and Masson trichrome. Immunohisto-
chemistry for CD3, CD68, and CD45Ro was obtained for
the phenotypic characterization of inflammatory cells. The
presence of an inflammatory infiltrate ≥14 leukocytes/mm2
including up to 4 monocytes/mm2, with the presence of
CD3+ T lymphocytes ≥7 cells/mm2 associated with evidence
of degeneration and/or necrosis of the adjacent
cardiomyocytes, was considered diagnostic for myocarditis.
Identification of conduction tissue followed the Aschoff
and Monckeberg morphologic criteria and positive immuno-
staining for HCN4.14
For transmission electron microscopy, additional samples
were fixed in 2% glutaraldehyde in 0.1 mol/L phosphate
buffer (pH 7.3), post fixed in osmium tetroxide, and proc-
essed following a standard schedule for embedding in Epon
resin. Ultrathin sections were stained with uranyl acetate
and lead hydroxide.
Real-time polymerase chain reaction was performed on 5
large tissue samples to search for the most common DNA
(adenovirus, cytomegalovirus, parvovirus B19, Epstein–Barr
virus, human herpes virus 6, and herpes simplex virus 1
and 2) and RNA (enterovirus, influenza virus A and B, hepati-
tis C virus) cardiotropic viruses.
Patient serum was tested for the presence of circulating
cardiac autoantibodies using a standard indirect immunofluo-
rescence technique.12
Patient serum was screened for the presence of
antimyosin antibodies, detected by a human myosin ELISA
kit (Elabscience Biotechnology Co., Ltd.) and anti-Gb3 Ab
ELISA Kit (Biogen scarl-Ariano Irpino, AV) not commercial.
As controls, we used five normal sera from normal subjects
matched with patient for age and sex.
PBMC were isolated from whole blood using Ficoll density
gradient centrifugation (Cedarlane Laboratories) and cryopre-
served in nitrogen liquid. Thawed PBMC were stimulated with
Gb3 (1 μg/mL, Matreya LLC) and with SEB (800 ng/mL, SIGMA
Aldrich) for 18 h in culture medium (RPMI +10% FBS). IL-1β,
IL-6, IL-8, and TNF-α were quantified using ELLA system
(ProteinSimple).
PBMC were stained using the following monoclonal anti-
bodies: CD3-V500, CD4-V450, CD8-APCcy7, CD45RO-
PerCPcy5.5, and CD27-FITC from BD Biosciences and
CD56-PC7 from Bekman Coulter as previously described
(Cimini et al., Sci Rep 2017) and acquired to FACS Canto II.
Results
Macroscopic examination (Figure 1A) showed a diffuse hyper-
trophy of cardiac walls with left ventricular maximal wall
thickness of 25 mm located at IV septum. Thinning of poste-
rior and lateral LV wall to 7 mm with areas of sclerosis was
observed. Epicardial coronary arteries were normal.
Histology, electron-microscopy, and
immunohistochemistry
Large (up to 60 μ of transverse diameter at nuclear level),
regularly arranged and extremely vacuolated cardiomyocytes
were observed (Figure 1A). The interstitium was remarkably
widened because of fibrosis and extensive inflammatory infil-
trates mainly represented by CD3/CD45Ro positive activated
T lymphocytes focally associated with necrosis of adjacent
myocytes and consisting with severe myocarditis
(Figure 1A,B). Vacuoles at ultrastructural examination ap-
peared to contain myelin bodies suggesting a Fabry disease
with striking intracellular accumulation of glycosphingolipids
in the form of myelin bodies and a common evidence of
extracellular secretion (Figure 1C). Myocardial inflammation
was extended to several intramural coronary arteries (vasculi-
tis, Figure 1D), to segments of conduction tissue (Figure 1E)
and to subepicardial ganglia that often showed extensive cy-
tolysis (Figure 1F).
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Figure 1 Histological and ultrastructural changes of an explanted Fabry heart requiring transplantation because of an incoming ventricular fibrillation.
(A) Macroscopic examination of explanted heart showing by sequential cuts severe biventricular hypertrophy. (B) Extensive myocarditis associated to
remarkably hypertrophied and vacuolated cardiomyocytes affected by FDCM (H&E 200×). (C) Inflammatory cells being mainly represented by
C-activated T lymphocytes (immunohistochemistry with CD45Ro, 200×). (D) Ultrastructural examination showing cardiomyocyte vacuoles consisting
of myelin bodies massively secreted (arrows) in the interstitium. (E) Vasculitis of an intramural coronary artery (vessel diameter 180 μm) which wall
is infiltrated by glycosphingolipid vacuoles (200×). (F) It shows a section of the vacuolized conduction tissue (ct) infiltrated and damaged by
CD45Ro + T lymphocytes (immunohistochemistry 200×). (G) Subepicardial neuron ganglion extensively infiltrated and damaged by T lymphocytes.
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Anti-heart, anti-myosin, and anti-Gb3 antibodies
They were found all elevated (Figure 2) compared with nor-
mal controls.
We therefore tested the ability of Gb3 to induce inflamma-
tory cytokine release by PBMC in Fabry patient and in a
healthy control. Results showed that PBMC from Fabry pa-
tients respond to Gb3 stimulation producing high amount of
inflammatory cytokines (IL1-β, IL-6, IL-8, and TNF-α)
(Figure 2).
Moreover, the phenotypic analysis of PBMC showed a
lower frequency of CD8 (9.2% in PT vs. 19.3% in CTRL) and
NKT cells (1.6% in PT vs. 2.4% in CTRL) in Fabry patient re-
spect to healthy donor, suggesting a possible homing to pe-
ripheral tissues. Interestingly, both CD8 and NKT cells from
Fabry patient showed a skewed differentiation profile with
a higher frequency of memory subsets (Figure 2I) when com-
pared to a healthy control. In contrast, no differences were
observed in CD4 T cells.
Statistical analysis
Data are presented as mean ± SD. A value of P < 0.05
was considered as significant. The difference between two
groups was determined by unpaired t-test for continuous
variables.
Discussion
Resistance to ERT is a major therapeutic challenge for pa-
tients with FDCM. Indeed, while it is recognized that
early ERT administration, particularly in pre-hypertrophic
FDCM, prevents progression of the disease, the advanced
form is believed to be insensitive/irreversible. Cause of
ERT resistance is still unclear although expansion of intersti-
tial space and myocardial fibrosis seem to play a role. To
this regard, there is growing evidence that the initial mech-
anism of interstitial damage might be an immune-mediated
myocardial inflammation induced by chronic secretion of
the highly immunogenic Gb3 by affected Fabry cells.
Gb3 secretion and membrane exposition by cardiomyocytes
is a common ultrastructural finding (see Figure 1C), particu-
larly in remarkably engulfed cells and explains why FD pa-
tients may survive many decades even in the absence of
GAL activity. Catabolism of circulating Gb3 into lipoproteins
by hepatocytes would concur to the compensatory
mechanism.
Recently, myocardial inflammation has been evaluated in a
large FDCM population receiving a diagnostic endomyocardial
biopsy.1 An increasing incidence of myocarditis has been doc-
umented from 33% of FDCM patients in pre-hypertrophy to
72% of those with advanced (>20 mm of LV maximal wall
thickness) disease. Myocardial inflammation was associated
with a negative PCR for viral genomes and a positive serology
for anti-heart and anti-myosin antibodies suggesting an
immune-mediated mechanism.
In the present report, an incoming ventricular fibrillation
required a cardiac transplantation in a patient with an ad-
vanced FDCM, resistant to ERT administration. Pathology of
the explanted heart revealed a severe intracellular accumula-
tion of glycosphingolipids associated to an extensive
virus-negative myocarditis. Noteworthy, inflammation in-
volved all affected components of the myocardium including
cardiomyocytes, coronary vessels, conduction tissue, and car-
diac ganglions. Particularly, inflammations of conduction tis-
sue and of neuron ganglia are unreported in FDCM,
because of the difficulty to include them, mostly the latter,
in an endomyocardial biopsy, while they played a major role
on the electrical instability that required heart replacement.
Diffuse myocardial inflammation in our FDCM patient sug-
gests an auto-reactive myocarditis vs. Gb3 released/
membrane exposed by Fabry cells.
This hypothesis is supported by the patient’s high serologic
titre for anti-Gb3 antibodies, by the inflammatory cytokines
released in response to Gb3 stimulation and by the memory
phenotype of CD8 and NKT cells.
The initial myocardial damage induced by anti-Gb3 im-
mune reaction would be followed by the release of segre-
gated antigens from insulted myocytes (i.e. myosin)
enhancing and perpetuating an autoimmune inflammation
(see Figure 3). Other organs (kidney and brain) or tissues
(vessels) can undergo the same pathway and give a reason
for disease progression.
If this hypothesis will be definitely confirmed by further
studies, ERT impact on FDCM and on FD in general could be
improved by a concomitant administration of low dose immu-
nosuppressive agents.
Case report
A 57-year-old male patient was admitted because of cardiac
arrest in severe left ventricular hypertrophy.
At the age of 55, he received the diagnosis of Fabry disease
(FD) after suffering from a stroke. At diagnosis, he had an
a-galactosidase activity of 1.51 nmol/mg/h (n.v.
31.4 ± 12.16), from a missense mutation c.1054G > C (p.
A352P). He was receiving ERT (alpha-agalsidase infusion at a
dosage of 0.2 mg/kg every other week) since diagnosis up
to the admission.
Since he was a child, he was suffering from a peripheral
neuropathy, with hypersensitivity to heat and paresthesia,
hand burning, bilateral hypoacusia, abdominal pain sometime
with diarrhoea. Normal sweating. At the age of 43, he
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Figure 2 Profile of anti-Gb3, anti-heart, anti-myosin abs, and PBMC in Fabry patient requiring heart transplantation. (A,B) Graphs show an increase of
antibody anti-Gb3(A) and anti-myosin (B) compared with normal controls. (C,D) Anti-heart autoantibodies in Fabry disease patients by indirect immu-
nofluorescence show a strongly positive fine striational pattern of positivity on human heart tissue in sera from patient, compared with control (D)
(×400). (E–H) PBMC from healthy control (CTRL) and Fabry patient (PT) were stimulated with Gb3 (1 μg/mL) for 18 h; cytokines (IL-1β, IL-6, IL-8,
and TNF-α) were quantified in culture supernatants by Ella system. (I) The differentiation profile of T cells (CD4, CD8) and NKT cells (CD3 + CD56+) were
analysed by flow cytometry. CD45RO identifies memory cell subsets: CD45RO + CD27+ cells represent central memory subset while CD45RO + CD27
cells represent effector memory subset.
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received a kidney biopsy for chronic renal failure:
creatininemia 4.49 mg/dL (n.v. 0.40–1.30), creatinine clear-
ance 17.6 mL/min (n.v. 80–160), proteinuria 3.2 g/die (n.v.
0–200mg/die). The biopsy was positive for glomerular sclero-
sis, nefroangiosclerosis with flogistic infiltration and foamy el-
ements of the intimal wall.
The kidney progressively deteriorated, and the patient re-
ceived a kidney transplant at the age of 52 after 18 months
of peritoneal dialysis. After transplant, the renal parameters
normalized promptly.
On the neurological side: at age 48, he had the first cere-
brovascular MRI due to some declared amnesia events. The
MRI described frontal and parietal periventricular gliosis, with
vascular space enlargements, with dolico-basilar
malformations; at age 55, he had the first stroke which led
to the FD diagnosis.
On the cardiac side: at age 47, he suffered from an initial
cardiomyopathy and hypertension with an initial concentric
hypertrophy which progressively increased to a maximal left
ventricular wall thickness of 25 mm. Cardiac MRI with con-
trast showed a generalized hyperintensity of the signal in
the LGE with a generalized intramural involvement. On the
cardiac conductance, the patient suffered since 2009 from
an atrial fibrillation with complete branch block. Over time,
severe arrhythmias brought him to a cardiac arrest at the
age of 57 (2019), which led the patient to be a candidate
for heart transplantation, performed in March 2019. Waiting
for the transplantation, he suffered from 2 further cardiac ar-
rests, 2 further strokes, and he was for 14 days under ECMO.
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Figure 3 Represents the hypothesized mechanism underlying autoimmune myocarditis in FDCM. This includes release of Gb3 from Fabry myocytes,
antigen exposition by CD1d molecule on dendritic antigen presenting cells which under the action of Toll-like receptor 4 activate the invariant natural
killer T cells to a humoral (including anti-glycosphingolipid antibodies) and cellular immune response. Cell necrosis is enhanced and perpetuated by
anti-myosin abs.
1336 A. Frustaci et al.
ESC Heart Failure 2020; 7: 1331–1337
DOI: 10.1002/ehf2.12723
References
1. Desnick RJ, Ioannou YA, Eng CM. Alpha-
galactosidase a deficiency: Fabry dis-
ease. In Scriver C. R., Beaudet A. L., Sly
W. S., Valle D., eds. The metabolic and
molecular bases of inherited disease.
New York, NY: McGraw-Hall; 2001. p
3733–3774.
2. Desnick RJ. Fabry’s disease
(aGalactosidase A deficiency): an
X-linked nephropathy. In Lifton R.,
Somlo S., Giebisch G., Seldin D., eds. Ge-
netic Diseases of the Kidney. San Diego,
CA: Elsevier Academic Press; 2009. p
597–616.
3. Germain DP. Fabry disease. Orphanet J
Rare Dis 2010; 5: 1–49.
4. Thurberg BL, Fallon JT, Mitchell R, Aretz
T, Gordon RE, O’Callaghan MW. Cardiac
microvascular pathology in Fabry dis-
ease: evaluation of endomyocardial bi-
opsies before and after enzyme
replacement therapy. Circulation 2009;
119: 2561–2567.
5. Najafian B, Savarstad E, Bostad L,
Gubler MC, Tondel C, Whitley C, Mauer
M. Progressive podocyte injury and
globotriasylceramide (GL-3) accumula-
tion in young patients with Fabry dis-
ease. Kidney Int 2011; 79: 663–670.
6. Chimenti C, Morgante E, Tanzilli G,
Mangieri E, Critelli G, Russo MA,
Frustaci A. Angina in Fabry disease re-
flects coronary small vessel disease. Circ
Heart Fail 2008; 1: 161–169.
7. von Scheidt W, Eng CM, Fitzmaurice TF,
Erdmann E, Hubner G, Olsen EG,
Christomanou H, Kandolf R, Bishop DF,
Desnick RJ. An atypical variant of
Fabry’s disease with manifestations con-
fined to the myocardium. N Engl J Med
1991; 324: 395–399.
8. Shiffmann R, Murray GJ, Treco D, Dan-
iel P, Sellos-Moura M, Quirk JM, Zirzow
GC, Borowski M, Loveday K, Anderson T.
Infusion of alphagalactosidase A reduces
tissue globotriaosylceramide storage in
patients with Fabry disease. Proc Natl
Acad Sci U S A 2000; 97: 365–370.
9. Schiffmann R, Floeter MK, Dambrosia
JM, Gupta S, Moore DF, Sharabi Y,
Khurana RK, Brady RO. Enzyme replace-
ment therapy improves peripheralnerve
and sweat function in Fabry disease.
Muscle Nerve 2003; 28: 703–710.
10. Tondel C, Bostad L, LarsenK K.
Agalsidase benefits renal histology in
young patients with Fabry disease. J
Am Soc Nephrol 2013; 24: 137–148.
11. Rombach SM, Smid BE, Bouwman MG,
Linthorst GE, Dijkgraaf MG, Hollak CE.
Long term enzyme replacement therapy
for Fabry disease: effectiveness on kid-
ney, heart and brain. Orphanet J Rare
Dis 2013; 8: 47.
12. Weidemann F, Niemann M, Stork S,
Breunig F, Beer M, Sommer C, Herr-
mann S, Ertl G, Wanner C. Long-term
outcome of enzyme replacement ther-
apy in advanced Fabry disease: evidence
for disease progression towards serious
complications. J Intern Med 2013; 274:
331–341.
13. Frustaci A, Verardo R, Grande C, Galea
N, Piselli P, Carbone I, Alfarano M,
Russo MA, Chimenti C. Immune-medi-
ated myocarditis in Fabry disease cardio-
myopathy. J Am Heart Assoc 2018; 7:
e009052.
14. Frustaci A, Verardo R, Grande C, Galea
N, Chimenti C. Arrhythmic phenotype
of myocarditis sustained by a prominent
infiltration of conduction tissue. Circ
Cardiovasc Imaging 2019; 12: e009448
Epub 2019 Jul 29.
Fabry cardiomyopathy: Gb3-induced auto-reactive panmyocarditis requiring heart transplantation 1337
ESC Heart Failure 2020; 7: 1331–1337
DOI: 10.1002/ehf2.12723
